What is it about?
About novel targeted agents in HCC
Featured Image
Why is it important?
Because progress in HCC therapeutics is extremely slow
Read the Original
This page is a summary of: Regorafenib: a newly approved drug for advanced hepatocellular carcinoma, Future Oncology, August 2017, Future Medicine,
DOI: 10.2217/fon-2017-0237.
You can read the full text:
Contributors
The following have contributed to this page
